Latest news with #SAPIEN
Yahoo
25-07-2025
- Business
- Yahoo
Edwards Lifesciences Corp (EW) Q2 2025 Earnings Call Highlights: Strong Sales Growth and Raised ...
Total Sales: $1.53 billion, a growth of 10.6% year-over-year. TAVR Sales: $1.1 billion, increased by 7.8% over the prior year. TMTT Sales: $133 million, grew 57% year-over-year. Surgical Sales: $267 million, increased by 6.8% over the prior year. Adjusted EPS: $0.67 for the quarter. GAAP EPS: $0.57, including a one-time charge related to external investments. Adjusted Gross Profit Margin: 77.6% for the quarter. SG&A Expenses: $502 million, 32.8% of sales. R&D Expenses: $276 million, 18% of sales. Adjusted Operating Profit Margin: 28.2% for the quarter. Cash and Cash Equivalents: Approximately $3 billion as of June 30. Full-Year Sales Growth Guidance: Raised to 9% to 10%. Full-Year Adjusted EPS Guidance: High end of the original range of $2.40 to $2.50. Third Quarter Sales Guidance: $1.46 billion to $1.54 billion. Third Quarter Adjusted EPS Guidance: $0.54 to $0.60. Warning! GuruFocus has detected 4 Warning Signs with EW. Release Date: July 24, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Edwards Lifesciences Corp (NYSE:EW) reported double-digit sales growth in Q2 2025, with total sales of $1.53 billion, a 10.6% increase, surpassing expectations. The company raised its full-year 2025 sales growth guidance to 9% to 10% and adjusted EPS guidance to the high end of the original range of $2.40 to $2.50. The Transcatheter Aortic Valve Replacement (TAVR) segment saw global sales increase by 7.8%, driven by the adoption of SAPIEN technology and recent approvals for asymptomatic indications. The Transcatheter Mitral and Tricuspid Therapies (TMTT) segment achieved a 57% sales growth, with significant contributions from PASCAL and EVOQUE technologies. Edwards Lifesciences Corp (NYSE:EW) maintains a strong balance sheet with approximately $3 billion in cash and cash equivalents, providing financial flexibility for future investments and share repurchases. Negative Points The company's adjusted gross profit margin decreased to 77.6% from 80% in the same period last year, impacted by additional manufacturing expenses and foreign exchange rates. Despite strong performance, the company faces potential headwinds from tariffs and the planned acquisition of JenaValve, which could negatively impact earnings per share. The exit of a competitor in Europe presents a challenge in maintaining market share, as Edwards Lifesciences Corp (NYSE:EW) needs to justify its higher price point compared to competitors. The company anticipates increased SG&A spending in the second half of the year, which could pressure operating margins. The potential impact of changes in the National Coverage Determination (NCD) for TAVR remains uncertain, which could affect future growth and market dynamics. Q & A Highlights Q: What drove the better-than-expected performance in US TAVR, and is the asymptomatic indication already impacting results? A: Bernard Zovighian, CEO, explained that the quarter exceeded expectations due to a renewed focus on TAVR, driven by the early TAVR study, which sparked conversations in the clinical community. Although the asymptomatic indication is not yet a major factor, the focus on managing severe aortic stenosis patients has increased. Larry Wood, Group President of TAVR, added that the attention on patient management has improved, even if asymptomatic patients are not yet significantly contributing. Q: Can you provide insights into TAVR performance outside the US, particularly in Europe and Japan? A: Daniel Lippis, Corporate Vice President, noted that the rollout of the S3 platform in Europe is progressing well, with positive feedback from physicians. The recent asymptomatic indication is expected to be a long-term game changer. In Japan, Edwards is focused on expanding therapy due to significant undertreatment and an aging population. The company is working to regain market share lost to new competitors. Q: Why didn't Edwards raise EPS guidance more significantly, given the strong quarter and tariff improvements? A: Scott Ullem, CFO, stated that while the second quarter was strong, there are still headwinds, such as the anticipated negative impact from the JenaValve acquisition. Despite these challenges, Edwards raised its full-year EPS guidance to the high end of the original range. The company remains committed to long-term EPS growth beyond 2025. Q: What impact could the CMS NCD update have on TAVR, and what is the likelihood of moving to a single operator requirement? A: Larry Wood explained that updating the NCD is crucial for covering asymptomatic patients and streamlining operator and facility requirements. This could improve patient access and relieve capacity challenges. Moving to a single operator could optimize patient flow, allowing both surgeon-led and cardiology-led TAVR teams to operate, enhancing care efficiency. Q: How is Edwards addressing the competitive landscape in TMTT, particularly with EVOQUE and the potential for new entrants? A: Daveen Chopra, Corporate Vice President, emphasized the excitement around EVOQUE, with real-world outcomes matching or exceeding clinical trial results. The company is focused on continuous innovation, with plans for future generations of EVOQUE to enhance performance. Bernard Zovighian added that demand for EVOQUE is high, and Edwards is committed to meeting patient needs with ongoing innovation and evidence generation. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
24-07-2025
- Business
- Business Wire
Edwards Lifesciences Reports Second Quarter Results
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2025. 2025 Outlook Increasing Edwards sales growth guidance to 9-10% from 8-10% Increasing TAVR sales guidance to 6-7% from 5-7%; reiterating TMTT and Surgical sales guidance Increasing adjusted 1 EPS guidance to the high-end of $2.40 to $2.50 Expected clinical presentations: 7-year PARTNER 3 low-risk, ENCIRCLE, TRISCEND II sub-analysis 'We are pleased to report strong second quarter results that delivered double-digit sales growth. Based on our better-than-expected first half performance and the many catalysts across our portfolio, we are confident in our full-year outlook and are raising our sales and EPS guidance,' said Bernard Zovighian, CEO. 'Edwards is increasingly distinguished by our balanced portfolio of leading therapies across aortic, mitral and tricuspid which will position us for leadership for many years to come as we help even more patients around the world.' Transcatheter Aortic Valve Replacement (TAVR) In the second quarter, the company reported TAVR sales of $1.1 billion, which grew 8.9% versus the prior year or 7.8% on a constant currency basis. Constant currency growth was comparable in the United States and outside of the U.S. On a global basis, Edwards' competitive position and pricing remained stable. TAVR growth in the quarter was better than expected, as clinicians continue to adopt Edwards' best-in-class SAPIEN technology. In the U.S., the clinical conversations around the EARLY TAVR trial data are bringing a renewed focus to streamlining the management of patients with severe aortic stenosis (AS), enabling closer follow-up and more timely treatment of patients with aortic stenosis. Outside of the U.S., the company continues to focus on the value of its differentiated technology and increasing therapy adoption, especially in areas where many patients go without care. In Europe, the exit of a competitor resulted in a rebalancing of market share and a modest contribution to Edwards' sales. In Japan, TAVR sales grew in the mid-single digits, an improvement over last quarter and consistent with the company's total sales growth in the region. Transcatheter Mitral and Tricuspid Therapies (TMTT) Edwards' unique TMTT portfolio of repair and replacement therapies to treat mitral and tricuspid diseases drove another quarter of impressive growth, with a meaningful contribution to overall company performance. Second quarter sales were $134.5 million or $133 million adjusted, representing growth of 61.9% year-over-year or 57.1% adjusted. Adoption of the company's differentiated PASCAL technology remains strong in both new and existing centers around the world. Edwards continues to see growing interest in the therapy, reinforcing the significant unmet needs of these patients. The EVOQUE system commercial launch is progressing well in the U.S. and Europe, with excellent real-world outcomes for patients consistent with the successful TRISCEND II clinical trial results. Edwards continues to see great demand for the therapy and continues to develop important evidence to support expansion globally. The company is pleased with the addition of its latest TMTT technology, the pioneering SAPIEN M3 mitral valve replacement system, which received CE Mark approval in Q2. Clinician feedback, while early, has been positive. With PASCAL, EVOQUE and the recent CE Mark of SAPIEN M3, Edwards' vision for TMTT has developed into a growth portfolio of groundbreaking transcatheter repair and replacement technologies, meeting the complex needs of underserved patients with mitral and tricuspid diseases. Surgical In Surgical, second quarter sales of $267 million increased 7.7% over the prior year, or 6.8% on a constant currency basis. The company continues to see positive procedure growth globally for the many patients best treated with its premium RESILIA tissue portfolio including the INSPIRIS, MITRIS and KONECT technologies. The company's KONECT aortic valved conduit received CE Mark approval in Europe during the quarter and the Surgical team made continued progress advancing important innovations around the world. Additional Financial Results For the quarter, the gross profit margin was 77.5%, in-line with the company's expectations, compared to 79.9% in the same period last year. This year-over-year change was driven by additional manufacturing expenses related to the expansion of new therapies as well as foreign exchange. Selling, general and administrative (SG&A) expenses in the second quarter were $502 million, or 32.8% of sales compared to $448 million in the same period last year. The company expects increased SG&A spending in the second half of the year due to deferral of certain spending year-to-date as well as anticipated spending related to JenaValve. Research and development (R&D) expense was $276 million in the quarter or 18.0% of sales, compared to $272 million or 19.8% of sales in the same period last year. This increase in spending and decrease in R&D as a percentage of sales reflects Edwards' strategic prioritization of investments in its expanding structural heart portfolio. Operating profit margin in the second quarter of 26.8%, or 28.2% adjusted, benefitted from the company's better-than-expected sales performance and the deferral of certain spending to the second half of the year. Cash and cash equivalents were approximately $3 billion as of June 30, 2025. Total debt was approximately $600 million. Outlook Edwards is increasing its full-year total company sales growth guidance to 9% to 10% with sales of $5.9 billion to $6.1 billion. In addition, the company is increasing its underlying growth rate guidance for TAVR to 6% to 7%, driven by strong performance, and its sales guidance range for TAVR to $4.3 billion to $4.5 billion. Sales guidance for the company's TMTT and Surgical product groups remains unchanged. The company now expects full-year adjusted EPS to be at the high end of its original range of $2.40 to $2.50. For the third quarter, the company projects total sales to be between $1.46 and $1.54 billion and adjusted EPS of $0.54 to $0.60. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at and follow us on LinkedIn, Facebook, Instagram and YouTube. Conference Call and Webcast Information The company will be hosting a conference call today at 2:00 p.m. PT to discuss its second quarter results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the 'Investor Relations' section of the Edwards website at or This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements can sometimes be identified by the use of words such as 'may,' 'will,' 'should,' 'anticipate,' 'believe,' 'plan,' 'project,' 'estimate,' 'forecast,' 'potential,' 'predict,' "early clinician feedback," 'expect,' 'intend,' 'guidance,' 'outlook,' 'optimistic,' 'aspire,' 'confident' or other forms of these words or similar expressions and include, but are not limited to, statements made by Mr. Zovighian and statements regarding the third quarter and fiscal year 2025 financial guidance, our expected growth and accelerating growth due to, among other things, asymptomatic TAVR approval; global adoption of, and differentiated features of, our devices; progress of the EVOQUE commercial launch; feedback on SAPIEN M3; our ability to deliver significant value to patients, healthcare ecosystem and shareholders; expansion of evidence, approvals, clinical trial outcomes and impacts; patient outcomes; the highlights in the Guidance and Outlook section and the information in the Outlook section. No inferences or assumptions should be made from statements of past performance, efforts, or results which may not be indicative of future performance or results. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain, difficult to predict, and may be outside of the company's control. The company's forward-looking statements speak only as of the date on which they are made and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. If the company does update or correct one or more of these statements, investors and others should not conclude that the company will make additional updates or corrections. Edwards' guidance reflects the Company's current estimates of the impact from tariffs that are in effect or have been announced as of the time of this press release and assumes such tariffs remain in place for the remainder of 2025. Any modification to such tariffs, or any new tariffs, could have a material impact on the Company's future financial results and guidance. Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements include risk and uncertainties associated with the risks detailed in the company's filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2024, and its other filings with the SEC. These filings, along with important safety information about our products, may be found at Edwards, Edwards Lifesciences, the stylized E logo, EARLY TAVR, ENCIRCLE, EVOQUE, INSPIRIS, KONECT, MITRIS, PARTNER, PARTNER II, PARTNER 3, PASCAL, RESILIA, SAPIEN, SAPIEN M3, SAPIEN 3, SAPIEN 3 Ultra, TRISCEND, and TRISCEND II are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners. (in millions, except per share data) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Net sales $ 1,532.2 $ 1,369.4 $ 2,944.9 $ 2,699.3 Cost of sales 344.4 275.5 646.0 562.4 Gross profit 1,187.8 1,093.9 2,298.9 2,136.9 Selling, general, and administrative expenses 502.0 447.5 967.7 875.9 Research and development expenses 276.2 271.8 530.8 528.5 Certain litigation expenses 15.5 8.1 26.4 17.0 Separation costs 4.2 — 8.4 — Other operating income (21.3 ) — (40.4 ) — Operating income, net 411.2 366.5 806.0 715.5 Interest income, net (37.4 ) (15.5 ) (73.9 ) (32.0 ) Loss on impairment 47.1 — 47.1 — Other non-operating expense (income), net 1.3 (2.0 ) (1.3 ) (7.7 ) Income from continuing operations before provision for income taxes 400.2 384.0 834.1 755.2 Provision for income taxes 64.3 20.0 134.6 66.3 Net income from continuing operations 335.9 364.0 $ 699.5 $ 688.9 (Loss) income from discontinued operations, net of tax (4.4 ) 1.0 (11.6 ) 27.1 Net income 331.5 365.0 687.9 716.0 Net loss attributable to noncontrolling interest (1.7 ) (1.3 ) (3.3 ) (2.2 ) Net income attributable to Edwards Lifesciences Corporation $ 333.2 $ 366.3 $ 691.2 $ 718.2 Earnings (loss) per share: Basic: Continuing operations $ 0.58 $ 0.61 $ 1.20 $ 1.15 Discontinued operations $ (0.01 ) $ — $ (0.02 ) $ 0.04 Basic earnings per share $ 0.57 $ 0.61 $ 1.18 $ 1.19 Diluted: Continuing operations $ 0.57 $ 0.61 $ 1.20 $ 1.15 Discontinued operations $ (0.01 ) $ — $ (0.02 ) $ 0.04 Diluted earnings per share $ 0.56 $ 0.61 $ 1.18 $ 1.19 Weighted-average common shares outstanding: Basic 587.0 602.1 586.9 601.8 Diluted 587.9 604.3 587.9 604.2 Operating statistics from continuing operations As a percentage of net sales: Gross profit 77.5 % 79.9 % 78.1 % 79.2 % Selling, general, and administrative expenses 32.8 % 32.7 % 32.9 % 32.4 % Research and development expenses 18.0 % 19.8 % 18.0 % 19.6 % Operating income 26.8 % 26.8 % 27.4 % 26.5 % Income before provision for income taxes 26.1 % 28.0 % 28.3 % 28.0 % Net income from continuing operations 21.9 % 26.6 % 23.8 % 25.5 % Effective tax rate 16.1 % 5.2 % 16.1 % 8.8 % Expand ____________________ Note: Numbers may not calculate due to rounding. Expand EDWARDS LIFESCIENCES CORPORATION Non-GAAP Financial Information To supplement the consolidated financial results prepared in accordance with Generally Accepted Accounting Principles ('GAAP'), the Company uses non-GAAP historical financial measures. Management makes adjustments to the GAAP measures for items (both charges and gains) that (a) do not reflect the core operational activities of the Company, (b) are commonly adjusted within the Company's industry to enhance comparability of the Company's financial results with those of its peer group, or (c) are inconsistent in amount or frequency between periods (albeit such items are monitored and controlled with equal diligence relative to core operations). The Company uses the terms "adjusted" and 'constant currency" when referring to non-GAAP sales from continuing operations and sales growth information, respectively, which excludes currency exchange rate fluctuations and newly acquired products. The Company uses the term 'adjusted' to also exclude certain litigation expenses, amortization of intangible assets, loss on impairment, and separation costs. Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results, and evaluating current performance. These non-GAAP financial measures are used in addition to, and in conjunction with, results presented in accordance with GAAP and reflect an additional way of viewing aspects of the Company's operations by investors that, when viewed with its GAAP results, provide a more complete understanding of factors and trends affecting the Company's business and facilitate comparability to historical periods. Non-GAAP financial measures are not prepared in accordance with GAAP; therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. A reconciliation of non-GAAP historical financial measures to the most comparable GAAP measure is provided in the tables below. Fluctuations in currency exchange rates impact the comparative results and sales growth rates of the Company's underlying business. Management believes that excluding the impact of currency exchange rate fluctuations from its sales growth provides investors a more useful comparison to historical financial results. The impact of the fluctuations has been detailed in the "Reconciliation of Sales by Product Group and Region." Guidance for sales and sales growth rates is provided on a "constant currency basis," and projections for diluted earnings per share, net income and growth, gross profit margin, and taxes are also provided on a non-GAAP basis, as adjusted, for the items identified above due to the inherent difficulty in forecasting such items without unreasonable efforts. The Company is not able to provide a reconciliation of the non-GAAP guidance to comparable GAAP measures due to the unknown effect, timing, and potential significance of special charges or gains, and management's inability to forecast charges associated with future transactions and initiatives. The items described below are adjustments to the GAAP financial results in the reconciliations that follow: Certain Litigation Expenses - The Company incurred certain litigation expenses of $10.9 million and $8.9 million in the first quarter of 2025 and 2024, respectively, and $15.5 million and $8.1 million for the second quarter of 2025 and 2024, respectively. Amortization of Intangible Assets - The Company recorded amortization expense related to developed technology and patents in the amount of $1.4 million and $0.5 million in the first quarter of 2025 and 2024, respectively, and $1.8 million and $1.2 million in the second quarter of 2025 and 2024, respectively. Separation Costs - The Company recorded expenses of $4.2 million in both the first and second quarter of 2025 related to consulting, legal, tax, and other professional advisory services related to the sale of Critical Care. Loss on Impairment - The Company recorded other-than-temporary loss on impairment of $47.1 million ($37.6 million net of tax) in the second quarter of 2025, related to the Company's determination to not exercise an option to acquire one of its cost method investments. Provision for Income Taxes - The income tax impacts of the expenses and gains discussed above are based upon the items' forecasted effect upon the Company's full year effective tax rate. Adjustments to forecasted items unrelated to the expenses and gains above, as well as impacts related to interim reporting, will have an effect on the income tax impact of these items in subsequent periods. Three Months Ended June 30, 2024 Net Sales Gross Profit Margin Operating Income, net Operating Profit Margin Net Income Diluted EPS Effective Tax Rate GAAP - Continuing Operations $ 1,369.4 79.9 % $ 366.5 26.8 % $ 364.0 $ 0.61 5.2 % Net loss attributable to noncontrolling interests — — — — 1.3 — — Total attributable to Edwards Lifesciences Corporation 1,369.4 79.9 % 366.5 26.8 % 365.3 0.61 5.2 % Non-GAAP adjustments: (A) (B) Certain litigation expenses — — 8.1 0.5 6.5 0.01 0.1 Amortization of intangible assets — 0.1 1.2 0.1 1.0 — — Prior period ongoing tax impacts — — — — 0.8 — — Adjusted $ 1,369.4 80.0 % $ 375.8 27.4 % $ 373.6 $ 0.62 5.3 % Expand Six Months Ended June 30, 2025 GAAP - Continuing Operations $ 2,944.9 78.1 % $ 806.0 27.4 % $ 699.5 $ 1.20 16.1 % Net loss attributable to noncontrolling interests — — — — 3.3 — — Total attributable to Edwards Lifesciences Corporation 2,944.9 78.1 % 806.0 27.4 % 702.8 1.20 16.1 % Non-GAAP adjustments: (A) (B) Certain litigation expenses — — 26.4 0.9 20.8 0.03 0.2 Amortization of intangible assets — 0.1 3.2 0.1 2.6 — — Separation costs — — 8.4 0.3 6.6 0.02 0.1 Loss on impairment — — — — 37.6 0.06 0.1 Adjusted $ 2,944.9 78.2 % $ 844.0 28.7 % $ 770.4 $ 1.31 16.5 % Expand Six Months Ended June 30, 2024 GAAP - Continuing Operations $ 2,699.3 79.2 % $ 715.5 26.5 % $ 688.9 $ 1.15 8.8 % Net loss attributable to noncontrolling interests — — — — 2.2 — — Total attributable to Edwards Lifesciences Corporation 2,699.3 79.2 % 715.5 26.5 % 691.1 1.15 8.8 % Non-GAAP adjustments: (A) (B) Certain litigation expenses — — 17.0 0.6 13.9 0.03 0.1 Amortization of intangible assets — — 1.7 0.1 1.4 — — Prior period ongoing tax impacts — — — 0.8 — — Adjusted $ 2,699.3 79.2 % $ 734.2 27.2 % $ 707.2 $ 1.18 8.9 % Expand ____________________ (A) See description of non-GAAP adjustments under "Non-GAAP Financial Information." (B) The tax effect on non-GAAP adjustments is calculated based upon the impact of the relevant tax jurisdictions' statutory tax rates on the Company's estimated annual effective tax rate, or discrete rate in the quarter, as applicable. The impact on the effective tax rate is reflected on each individual non-GAAP adjustment line item. Expand 2025 Adjusted 2024 Adjusted Sales by Product Group (QTD) - Continuing Operations 2Q 2025 2Q 2024 Change GAAP Growth Rate* Implantable Heart Failure Management 2Q 2025 Adjusted Sales FX Impact 2Q 2024 Adjusted Sales Constant Currency Growth Rate * Transcatheter Aortic Valve Replacement $ 1,130.9 $ 1,038.6 $ 92.3 8.9 % $ — $ 1,130.9 $ 11.3 $ 1,049.9 7.8 % Transcatheter Mitral and Tricuspid Therapies 134.5 83.0 51.5 61.9 % (1.5 ) 133.0 1.7 84.7 57.1 % Surgical Structural Heart 266.8 247.8 19.0 7.7 % — 266.8 2.4 250.2 6.8 % Total $ 1,532.2 $ 1,369.4 $ 162.8 11.9 % $ (1.5 ) $ 1,530.7 $ 15.4 $ 1,384.8 10.6 % Expand 2025 Adjusted 2024 Adjusted Sales by Product Group (YTD) - Continuing Operations YTD 2Q 2025 YTD 2Q 2024 Change GAAP Growth Rate* Implantable Heart Failure Management YTD 2Q 2025 Adjusted Sales FX Impact YTD 2Q 2024 Adjusted Sales Constant Currency Growth Rate * Transcatheter Aortic Valve Replacement $ 2,177.5 $ 2,046.5 $ 131.0 6.4 % $ — $ 2,177.5 $ (3.8 ) $ 2,042.7 6.6 % Transcatheter Mitral and Tricuspid Therapies 249.7 155.9 93.8 60.1 % (1.9 ) 247.8 (0.1 ) 155.8 59.1 % Surgical Structural Heart 517.7 496.9 20.8 4.2 % — 517.7 (2.2 ) 494.7 4.7 % Total $ 2,944.9 $ 2,699.3 $ 245.6 9.1 % $ (1.9 ) $ 2,943.0 $ (6.1 ) $ 2,693.2 9.3 % Expand 2025 Adjusted 2024 Adjusted Sales by Region (QTD) - Continuing Operations 2Q 2025 2Q 2024 Change GAAP Growth Rate* Implantable Heart Failure Management 2Q 2025 Adjusted Sales FX Impact 2Q 2024 Adjusted Sales Constant Currency Growth Rate * United States $ 889.7 $ 806.4 $ 83.3 10.3 % $ (1.5 ) $ 888.2 $ — $ 806.4 10.1 % Europe 378.2 332.2 46.0 13.8 % — 378.2 13.1 345.3 9.6 % Japan 95.3 86.5 8.8 10.2 % — 95.3 5.1 91.6 4.2 % Rest of World 169.0 144.3 24.7 17.1 % — 169.0 (2.8 ) 141.5 19.5 % Outside of the United States 642.5 563.0 79.5 14.1 % — 642.5 15.4 578.4 11.3 % Total $ 1,532.2 $ 1,369.4 $ 162.8 11.9 % $ (1.5 ) $ 1,530.7 $ 15.4 $ 1,384.8 10.6 % Expand ____________________ * Numbers may not calculate due to rounding. Expand
Hans India
12-07-2025
- General
- Hans India
SAPIEN FEELING - The Human-Centric Bias in a Symbiotic World
In the vast tapestry of life on Earth, Homo sapiens—modern humans—have long considered themselves the pinnacle of evolution. This sense of superiority, often unspoken but deeply ingrained, shapes our attitudes, behaviors, and policies toward the rest of the living world. Today, let us introduce and explore a new phrase: SAPIEN FEELING. Much like 'caste feeling' refers to an exclusive loyalty and pride in one's own social group, SAPIEN FEELING describes a mindset where humans love, prioritize, and value only their own species, often at the expense of other life forms. This article delves into the roots, manifestations, and consequences of this phenomenon, and why it is crucial to transcend it for the health of our planet. What is SAPIEN FEELING? SAPIEN FEELING is the exclusive emotional attachment and loyalty that humans feel toward their own species, coupled with a disregard or indifference toward other organisms. It manifests as: • Anthropocentrism: Viewing humans as the central or most significant entities on the planet. • Speciesism: Discriminating against non-human species, considering them inferior or less deserving of moral concern. • Dominion Mindset: Believing that humans have the right to control, exploit, or ignore other forms of life. This feeling is so pervasive that it often goes unnoticed, embedded in our language ('mankind,' 'man-made'), our laws (animal rights are minimal compared to human rights), and our daily choices (factory farming, deforestation, pollution). Roots of SAPIEN FEELING 1. Evolutionary Legacy: Our ancestors survived by prioritizing their own group. This in-group preference, once necessary for survival, now extends to our entire species. 2. Religious and Cultural Narratives: Many traditions teach that humans are created in the image of a deity, or given dominion over the Earth. 3. Technological Mastery: Our ability to manipulate the environment reinforces the illusion of separateness and superiority. Manifestations in Modern Society • Environmental Exploitation: Forests are cleared, oceans are overfished, and species are driven to extinction, often with little regard for the broader ecological consequences. • Animal Rights Neglect: Billions of animals are raised and killed in inhumane conditions for food, clothing, or experimentation. • Urban Planning: Cities are designed with little consideration for the habitats of non-human creatures. • Climate Change: The human-centric pursuit of progress has led to global warming, threatening countless species—including our own. The Symbiotic Reality What SAPIEN FEELING ignores is the fundamental truth that life on Earth is interconnected. We live in a symbiotic world, where the health and survival of each species is tied to the well-being of others: • Pollinators like bees are essential for our food crops. • Trees produce the oxygen we breathe and absorb carbon dioxide. • Microbes in our soil and bodies are crucial for health. When we harm other organisms, we ultimately harm ourselves. Why Transcend SAPIEN FEELING? 1. Ecological Stability: Biodiversity ensures resilience against environmental shocks. 2. Ethical Responsibility: As the most powerful species, we have a duty to protect the vulnerable. 3. Long-term Survival: Our fate is bound to the fate of the planet. Moving Beyond: Toward Earth Empathy To overcome SAPIEN FEELING, we must cultivate Earth Empathy—a sense of kinship with all living beings. This means: • Education: Teaching ecological literacy and respect for all life. • Policy: Enacting laws that protect ecosystems, not just individual species. • Personal Choices: Adopting sustainable lifestyles, reducing consumption, and supporting conservation. Conclusion SAPIEN FEELING is a subtle but powerful bias that blinds us to our place in the web of life. By recognizing and challenging this mindset, we can begin to heal our relationship with the natural world and ensure a thriving future for all species—including Homo sapiens. Currently, most philanthropic giving is directed toward causes that benefit humans directly, such as education, health, and poverty alleviation. While these are undeniably important, this pattern reflects the very mindset of SAPIEN FEELING: prioritizing human welfare above the health of the entire biosphere. Spending more on planet rejuvenation—such as ecosystem restoration, biodiversity conservation, and climate action—would address the root causes of many human problems and help secure a sustainable future for all life. The logic is clear: a healthy planet underpins human health, food security, and long-term prosperity. Yet, environmental causes typically receive a much smaller share of philanthropic funding compared to human-centered initiatives. Recent trends show that overall charitable giving is rising and that there is growing awareness of environmental issues. However, the bulk of resources still flow toward human-focused philanthropy, often leaving environmental and planetary rejuvenation efforts underfunded. Rebalancing philanthropic priorities to invest more in the planet is not about neglecting human needs but about recognizing our interdependence with nature. Supporting planetary health is ultimately an investment in human well-being, as our survival depends on thriving ecosystems. In summary, if we are to move beyond SAPIEN FEELING and embrace a truly symbiotic worldview, redirecting more philanthropic resources toward planet rejuvenation is both logical and necessary. This shift would help address systemic challenges and ensure a resilient future for humans and all other life forms. Let us remember: we are not masters of the Earth, but participants in its grand symphony. Our survival depends on the health of the entire orchestra. Harish CP Yarlagadda Co-founder Dharmavana Nature Ark ( a non-profit biodiversity park) Hyderabad July 2025
Yahoo
23-05-2025
- Health
- Yahoo
Edwards' study demonstrates value in early aortic stenosis intervention
New research by Edwards Lifesciences has demonstrated that early intervention for severe aortic stenosis (AS) before symptoms develop improves patient outcomes and reduces the economic and resource burden on healthcare systems. Edwards' real-world study of more than 24,000 patients with severe AS demonstrated that prompt intervention resulted in an average of 2.2 fewer days spent in hospitals during patients' treatment, 80% fewer heart failure hospitalisations one year after treatment, and cost reductions of $36,000 per patient at the one-year point. The study results were presented as a late-breaking clinical trial at EuroPCR 2025, taking place in Paris, France, between 20 and 23 May. Larry Wood, Edwards' corporate vice president and transcatheter aortic valve replacement (TAVR) and surgical group president, said: 'We are dedicated to advancing robust evidence to help improve outcomes for patients with severe AS. 'These latest findings underscore the importance of early referral to a heart valve team and timely care of patients with severe AS, reducing the economic and resource burden for hospitals.' It is no surprise that Edwards is shining a light on early AS intervention. The medtech giant recently received approval from the US Food and Drug Administration (FDA) on an indication expansion for its SAPIEN 3 TAVR platform in the treatment of patients with asymptomatic severe AS. The approval was supported by data from Edwards' EARLY TAVR trial (NCT03042104). The results demonstrated that asymptomatic severe AS patients randomised to the company's TAVR experienced superior outcomes versus guideline-recommended clinical surveillance (watchful waiting). At a median follow-up of 3.8 years, the data showed that 26.8% of the 455 patients in the trial's TAVR arm experienced death, stroke or unplanned cardiovascular hospitalisation versus 45.3% of the 446 patients in the clinical surveillance arm. According to GlobalData analysis, the global TAVR market is forecast to reach a valuation of around $13.7bn by 2033, up from $6.16bn in 2023. GlobalData's US Healthcare Facility Invoicing Database indicates that Edwards Lifesciences is currently the TAVR market leader, holding more than a 60% share of the US TAVR market. But change may be afoot. Medtronic recently released two-year results from a clinical trial comparing its Evolut system to Edwards' SAPIEN, with the data showing that the Evolut system led to significantly less bioprosthetic valve dysfunction, five times less prosthetic valve thrombosis, and nine times less haemodynamic structural valve dysfunction than the SAPIEN system. According to GlobalData analysis, the Evolut system could become the preferred option among healthcare professionals for patients with symptomatic severe AS and small aortic annulus categories, as evaluated in the trial. "Edwards' study demonstrates value in early aortic stenosis intervention" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
23-05-2025
- Health
- Yahoo
Edwards' study demonstrates value in early aortic stenosis intervention
New research by Edwards Lifesciences has demonstrated that early intervention for severe aortic stenosis (AS) before symptoms develop improves patient outcomes and reduces the economic and resource burden on healthcare systems. Edwards' real-world study of more than 24,000 patients with severe AS demonstrated that prompt intervention resulted in an average of 2.2 fewer days spent in hospitals during patients' treatment, 80% fewer heart failure hospitalisations one year after treatment, and cost reductions of $36,000 per patient at the one-year point. The study results were presented as a late-breaking clinical trial at EuroPCR 2025, taking place in Paris, France, between 20 and 23 May. Larry Wood, Edwards' corporate vice president and transcatheter aortic valve replacement (TAVR) and surgical group president, said: 'We are dedicated to advancing robust evidence to help improve outcomes for patients with severe AS. 'These latest findings underscore the importance of early referral to a heart valve team and timely care of patients with severe AS, reducing the economic and resource burden for hospitals.' It is no surprise that Edwards is shining a light on early AS intervention. The medtech giant recently received approval from the US Food and Drug Administration (FDA) on an indication expansion for its SAPIEN 3 TAVR platform in the treatment of patients with asymptomatic severe AS. The approval was supported by data from Edwards' EARLY TAVR trial (NCT03042104). The results demonstrated that asymptomatic severe AS patients randomised to the company's TAVR experienced superior outcomes versus guideline-recommended clinical surveillance (watchful waiting). At a median follow-up of 3.8 years, the data showed that 26.8% of the 455 patients in the trial's TAVR arm experienced death, stroke or unplanned cardiovascular hospitalisation versus 45.3% of the 446 patients in the clinical surveillance arm. According to GlobalData analysis, the global TAVR market is forecast to reach a valuation of around $13.7bn by 2033, up from $6.16bn in 2023. GlobalData's US Healthcare Facility Invoicing Database indicates that Edwards Lifesciences is currently the TAVR market leader, holding more than a 60% share of the US TAVR market. But change may be afoot. Medtronic recently released two-year results from a clinical trial comparing its Evolut system to Edwards' SAPIEN, with the data showing that the Evolut system led to significantly less bioprosthetic valve dysfunction, five times less prosthetic valve thrombosis, and nine times less haemodynamic structural valve dysfunction than the SAPIEN system. According to GlobalData analysis, the Evolut system could become the preferred option among healthcare professionals for patients with symptomatic severe AS and small aortic annulus categories, as evaluated in the trial. "Edwards' study demonstrates value in early aortic stenosis intervention" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
